Skip to main content

Elizabeth Nielson

Elizabeth Nielson

Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a Site Co-Principal Investigator and therapist for an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder, and has served as a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, psilocybin-assisted treatment of treatment resistant depression, and earlier phase 2 and 3 trials of MDMA-assisted psychotherapy. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings.

Psilocybin Facilitator Training under State Regulatory Frameworks

Oregon’s Measure 109 allowed the first regulated psilocybin facilitator training programs to launch in late 2022. Just as psilocybin facilitators are beginning to get licensed and start practicing in Oregon, other states are building similar regulatory frameworks. The need for education and professional standards is clear and a number of governmental agencies and independent organizations are involved in meeting it. This talk will give an overview of education requirements and how education programs are regulated in Oregon, discuss professional organizations and efforts at creating accreditation systems, and frame the key questions for the sustainable growth of robust training programs in states where similar opportunities are soon to open.
Policy
Exclusive Deal!
Skip to content